Product
Local Standard of Care
1 clinical trial
2 indications
Indication
MeningiomaIndication
malignantClinical trial
Regorafenib for Recurrent Grade 2 and 3 Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)Status: Not yet recruiting, Estimated PCD: 2026-12-01